Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin LymphomaTerminated
NCT04903197Phase 1Updated Apr 1, 2026
Sponsor: Novartis Pharmaceuticals
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Australia, China, Germany, Italy, Japan +2 more
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal CancersCompleted
NCT03798626Phase 1Updated Apr 1, 2026
Sponsor: Novartis Pharmaceuticals
Colorectal Cancer · Gastroesophageal Cancer · Renal Cell Carcinoma
United States, Australia, Belgium, Canada, Chile +10 more
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid TumorsRecruiting
NCT05868629N/AUpdated Apr 1, 2026
Sponsor: Novartis Pharmaceuticals
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
United States
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617Recruiting
NCT07054346Phase 1Updated Apr 1, 2026
Sponsor: Thomas Hope
Prostate Cancer · Prostate Cancer (Diagnosis) · High-risk Prostate Cancer · Localized Prostate Carcinoma
United States
Managed Access Programs for LDK378, CeritinibNo Longer Available
NCT05100134N/AUpdated Apr 1, 2026
Sponsor: Novartis Pharmaceuticals
Anaplastic Lymphoma Kinase (ALK)- Positive Tumors · Non-small Cell Lung Cancer (NSCLC)
A Study of Zigakibart in Adults With IgA NephropathyActive Not Recruiting
NCT05852938Phase 3Updated Apr 1, 2026
Sponsor: Novartis Pharmaceuticals
IgA Nephropathy · Immunoglobulin A Nephropathy
United States, Argentina, Australia, Belgium, Brazil +18 more
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMRCompleted
NCT06130540Phase 1Updated Apr 1, 2026
Sponsor: Novartis Pharmaceuticals
Giant Cell Arteritis · Polymyalgia Rheumatica
United States, Czechia, Italy, Portugal, Spain +1 more
Epidemiology and Treatment of HR+/HER2- Breast Cancer in EnglandCompleted
NCT07498413N/AUpdated Apr 1, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
United Kingdom
Development of a Novel Functional Eye-Tracking Software Application for Multiple SclerosisRecruiting
NCT05061953N/AUpdated Apr 1, 2026
Sponsor: Innodem Neurosciences
Multiple Sclerosis
Canada
Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaRecruiting
NCT07375355N/AUpdated Apr 1, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myeloid Leukemia in Chronic Phase
China
A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian FederationActive Not Recruiting
NCT06625333N/AUpdated Apr 1, 2026
Sponsor: Novartis Pharmaceuticals
HR+HER2- Advanced Breast Cancer
Russia
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationCompleted
NCT04677595Phase 2Updated Mar 31, 2026
Sponsor: Novartis Pharmaceuticals
Non-Small Cell Lung Cancer (NSCLC)
China
Safety and Efficacy of RHH646 for Knee OsteoarthritisCompleted
NCT05816395Phase 2Updated Mar 31, 2026
Sponsor: Novartis Pharmaceuticals
Osteoarthritis, Knee
United States, Argentina, Denmark, Poland, Spain
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)Completed
NCT04930094Phase 3Updated Mar 31, 2026
Sponsor: Novartis Pharmaceuticals
Giant Cell Arteritis (GCA)
United States, Argentina, Australia, Austria, Belgium +22 more
Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSDCompleted
NCT04717635Phase 3Updated Mar 31, 2026
Sponsor: Novartis Pharmaceuticals
Adult Onset Still's Disease
Japan
Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee OsteoarthritisCompleted
NCT04886258Phase 2Updated Mar 31, 2026
Sponsor: Novartis Pharmaceuticals
Symptomatic Knee Osteoarthritis
United States, Argentina, Czechia, Germany, Hungary +3 more
A Proof-of-concept Study to Examine QUC398 in Participants With Knee OATerminated
NCT05462990Phase 2Updated Mar 31, 2026
Sponsor: Novartis Pharmaceuticals
Osteoarthritis, Knee
United States, Australia, Denmark, France, Spain
A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.Completed
NCT07032272Phase 1Updated Mar 30, 2026
Sponsor: Novartis Pharmaceuticals
Autoimmune and Chronic Inflammatory Diseases
United States
Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)Recruiting
NCT07290270N/AUpdated Mar 30, 2026
Sponsor: Novartis Pharmaceuticals
Metastatic Prostate Cancer
China
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALLRecruiting
NCT07250087Phase 1Updated Mar 27, 2026
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
United States
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate CancerActive Not Recruiting
NCT04663997Phase 2Updated Mar 27, 2026
Sponsor: Canadian Cancer Trials Group
Prostate Cancer
Canada
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesActive Not Recruiting
NCT05552469Phase 1Updated Mar 27, 2026
Sponsor: Novartis Pharmaceuticals
Myeloid Diseases
United States, France, Germany, Hong Kong, Italy +3 more
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CMLNot Yet Recruiting
NCT07493408Phase 2Updated Mar 25, 2026
Sponsor: The University of Hong Kong
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) · Blastic Transformation of Chronic Myeloid Leukemia · Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL) · Haematopoietic Stem Cell Transplant, Allogeneic
Hong Kong
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDSActive Not Recruiting
NCT00819546Phase 1Updated Mar 25, 2026
Sponsor: Richard Stone, MD
Acute Myeloid Leukemia · Myelodysplastic Syndrome
United States
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff TendinopathyTerminated
NCT05722522Phase 3Updated Mar 24, 2026
Sponsor: Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
United States, Argentina, Bulgaria, Canada, Czechia +2 more

Previous page Next page